Cargando…

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities

Kras-driven non–small-cell lung cancers (NSCLCs) are a leading cause of death with limited therapeutic options. Many NSCLCs exhibit high levels of Ezh2, the enzymatic subunit of polycomb repressive complex 2 (PRC2). We tested Ezh2 inhibitors as single agents or before chemotherapy in mice with ortho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serresi, Michela, Siteur, Bjorn, Hulsman, Danielle, Company, Carlos, Schmitt, Matthias J., Lieftink, Cor, Morris, Ben, Cesaroni, Matteo, Proost, Natalie, Beijersbergen, Roderick L., van Lohuizen, Maarten, Gargiulo, Gaetano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279402/ https://www.ncbi.nlm.nih.gov/pubmed/30487290 http://dx.doi.org/10.1084/jem.20180801

Ejemplares similares

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities
por: Lieftink, Cor, et al.
Publicado: (2021)

Functional antagonism of chromatin modulators regulates epithelial-mesenchymal transition
por: Serresi, Michela, et al.
Publicado: (2021)

USP15 Deubiquitinase Safeguards Hematopoiesis and Genome Integrity in Hematopoietic Stem Cells and Leukemia Cells
por: van den Berk, Paul, et al.
Publicado: (2020)

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2018)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2021)

Tight regulation of ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic stem cells
por: Lancini, Cesare, et al.
Publicado: (2014)

Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses
por: Jiang, Ben, et al.
Publicado: (2023)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
por: Ratz, Leonie, et al.
Publicado: (2022)

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine
por: Spanjaard, Aldo, et al.
Publicado: (2022)

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen
por: Schepers, Arnout, et al.
Publicado: (2021)

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation
por: Kostova, Elena B., et al.
Publicado: (2015)

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
por: Palit, Sander A. L., et al.
Publicado: (2021)

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2021)

Inducing and exploiting vulnerabilities for the treatment of liver cancer
por: Wang, Cun, et al.
Publicado: (2019)

The RECQL helicase prevents replication fork collapse during replication stress
por: Benedict, Bente, et al.
Publicado: (2020)

High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells
por: Tuijnenburg, Paul, et al.
Publicado: (2019)

Synthetic Vulnerabilities in the KRAS Pathway
por: Roman, Marta, et al.
Publicado: (2022)

Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition
por: Koppens, Martijn AJ, et al.
Publicado: (2016)

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
por: Wang, Yanxiao, et al.
Publicado: (2017)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer
por: Jin, Haojie, et al.
Publicado: (2020)

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
por: Pietersen, Alexandra M, et al.
Publicado: (2008)

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer
por: Prekovic, Stefan, et al.
Publicado: (2021)

Developing SHP2-based combination therapy for KRAS-amplified cancer
por: Li, Tianxia, et al.
Publicado: (2023)

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma
por: Li, Yuchan, et al.
Publicado: (2022)

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
por: Luo, Yongde, et al.
Publicado: (2021)

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
por: Palit, Sander AL, et al.
Publicado: (2019)

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer
por: Zhou, Yangyang, et al.
Publicado: (2022)

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2023)

A simple, wide bandwidth, biopotential amplifier to record pacemaker pulse waveform
por: Bifulco, Paolo, et al.
Publicado: (2016)

The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens
por: Steele, J C, et al.
Publicado: (2006)

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors
por: van der Noord, Vera E., et al.
Publicado: (2023)

Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer
por: Aubert, Léo, et al.
Publicado: (2020)

KRAS is vulnerable to reversible switch-II pocket engagement in cells
por: Vasta, James D., et al.
Publicado: (2022)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
por: Puppe, Julian, et al.
Publicado: (2009)

Genetic and compound screens uncover factors modulating cancer cell response to indisulam
por: Pogacar, Ziva, et al.
Publicado: (2022)

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qqui1samh11toi360f9033rfbl